Table 6.

Evaluation of the plasma concentration of Immunoglobulin G (IgG) in mg/dL of 30 participants^# at T0, T1, T2, and T3.

Participants	T0	T1	T2	T3
ALC16	1.289	1.234	1.199	1.227
AMB03	1.254	1.210	1.230	*
BP26	1.164	1.166	1.005	1.034
C-A23	1.248	1.301	1.211	*
C-C36	1.741	1.720	1.507	1.886
CL12	1.448	1.498	1.222	1.261
CRS33	1.380	1.320	1.396	1.369
E-S01	1.255	1.014	1.040	1.153
EEV13	1.094	1.185	1.072	1.025
FAS05	1.013	1.021	1.262	**
HFS28	1.136	1.105	**	**
IMS35	1.881	1.895	2.047	2.097
J-S42	1.781	1.663	1.552	1.743
JPF18	1.770	1.095	1.680	1.405
JSF29	1.423	1.531	**	**
LS15	1.423	1.420	1.213	1.338
LOF29	1.458	1.403	1.304	1.590
MIV14	1.429	1.354	1.198	897
MPG17	1.143	1.098	1.074	1.130
NS07	1.607	1.485	1.565	1.460
NMA30	1.371	1.541	1.388	**
PBL27	1.718	1.636	1.820	**
SVR04	1.312	1.181	1.203	**
TAA10	1.211	1.164	1.093	1.137
VD19	1.247	1.189	1.177	1.164
VAR21	1.407	1.120	1.248	1.354
VAT34	1.192	1.138	1.217	1.034
VDR32	1.664	1.641	1.698	1.680
VLA11	1.278	1.234	1.154	1.110
WN37	1.047	1.179	1.126	*

T0 before treatment (screening); T1 (30 days), T2 (60 days) during treatment, and T3 (90 days) at the end of treatment.

*Participants who did not collected material for immunogenicity analyses at that visit.

**Discontinued participants.

IgG references values for adult individuals, 490 to 1.140 mg/dL.

^#Mislaid of material collected for immunogenicity analyzes from all visits by one participant.